Amryt Pharma Plc is a pharmaceutical company, which engages in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. It operates through the following segments: Commercial, Research and Development. The Commercial segment includes the financial results of the Group's two current commercial product lines, Imlan and Lojuxta. The Research and Development segment comprises the financial results of the Group’s two current research and development assets, AP101 and AP102. The company was founded by Joseph Amrit Wiley and Rory Peter Nealon on August 28, 2015 and is headquartered in Dublin, Ireland.